Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

MICROBOTS

Financiado

MICROBOTS – Unravel the power of MICRObial metaBOliTeS to prevent graft versus h...

MICROBOTS – Unravel the power of MICRObial metaBOliTeS to prevent graft versus host disease and cure leukemia relapse Allogeneic stem cell transplantation (allo-SCT) is the most common cellular immunotherapy for hematologic malignancies, but beneficial outcomes are limited by severe morbidity and mortality by graft-vs.-host disease (GVHD) and by... ver más

31/05/2029

KLINIKUM DER UNIVE...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

KLINIKUM DER UNIVERSITAET REGENSBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-09

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

KLINIKUM DER UNIVERSITAET RE...

2.00M€ | Lider

Proyectos interesantes

MicroT Microbiota-T cell interactions - antigen-specificity and reg... 2M€ Cerrado

AlloCure Deciphering cellular signalling to cure graft-versus-host di... 2M€ Cerrado

PowerMiT Leveraging the impact of gut microbes to advance the efficac... 2M€ Cerrado

T Cell Feedback T cell regulation by fed state bacterial metabolites 1M€ Cerrado

VACCIBIOME Cancer Vaccines and Gut Microbiome a rational approach to o... 2M€ Cerrado

BES-2013-063268 TRANSPLANTE AUTOLOGO DE CELULAS MADRE HEMATOPOYETICAS EN LA... 84K€ Cerrado

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 63 meses Fecha Inicio: 2024-02-09
Fecha Fin: 2029-05-31

Líder del proyecto

KLINIKUM DER UNIVERSITAET REGENSBURG

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Allogeneic stem cell transplantation (allo-SCT) is the most common cellular immunotherapy for hematologic malignancies, but beneficial outcomes are limited by severe morbidity and mortality by graft-vs.-host disease (GVHD) and by relapse as a consequence of insufficient antitumor immune response (graft-vs-leukemia, GVL). In allo-SCT patients, a diverse gut microbiome is associated with beneficial clinical outcomes and fecal microbiota transplantation (FMT) emerges as a promising therapeutic option for acute gastrointestinal GVHD patients. Yet, how the gut and tissue-associated microbiome governs immune function and tissue homeostasis remains poorly understood. We identified microbial signatures - i.e., configurations of microbial communities and their associated immune-modulatory metabolites - in allo-SCT patients that (i) favourably associate with clinical outcomes, (ii) can engage an Interferon (IFN)-I inducing pathway to induce tissue regeneration, and (iii) protect mice from immune-mediated tissue damage. We therefore hypothesize that gut and tissue-associated microbial consortia and their immune-modulatory metabolites serve as a game changer for allo-SCT. MICROBOTS will test this by (i) providing a thorough characterization of microbiome/metabolome-host interaction at the epithelial interface in allo-SCT patients with or without GVHD, relapse and undergoing FMT and (ii) evaluating the functional impact of identified microbial signatures in advanced preclinical models of GVL and GVHD. These novel insights will provide a template for the design of a Precision FMT approach with defined microbial-metabolite cocktails aimed to achieve robust and durable antitumor responses in allo-SCT patients as well as to improve tissue regeneration and minimize immune-mediated side effects (GVHD). This may induce a paradigm-shift in clinical allo-SCT protocols and potentially other T cell transfer therapies (CAR/TCR T cells) in cancer treatment as a whole.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores